Xuriden is owned by Wellstat Therap.
Xuriden contains Uridine Triacetate.
Xuriden has a total of 1 drug patent out of which 0 drug patents have expired.
Xuriden was authorised for market use on 04 September, 2015.
Xuriden is available in granule;oral dosage forms.
The generics of Xuriden are possible to be released after 10 July, 2023.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6258795||WELLSTAT THERAP||Acylated uridine and cytidine and uses thereof|| |
(3 months from now)
|Orphan Drug Exclusivity (ODE)||Sep 4, 2022|
Drugs and Companies using URIDINE TRIACETATE ingredient
Market Authorisation Date: 04 September, 2015
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic